TITLE

EVALUATION OF HYDRALAZINE (APRESOLINE) IN FIXED HYPERTENSION

AUTHOR(S)
Drenick, Enst J.; Kalmanson, George M.
PUB. DATE
August 1956
SOURCE
Angiology;Aug1956, Vol. 7 Issue 4, p368
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Among approximately 300 patients with hypertensive disease 38 patients were found to have fixed hypertension, even during sleep. These were all treated with hydralazine. Thirteen patients also received hexamethonium. Thirty-two per cent have been maintained at normotensive levels for 5 to 33 months, an average of 19 months. Two patients in this group required hexamethonium also. Eight per cent had an inconstant response to medication. Eleven per cent had an excellent response to hydralazine but it was discontinued because of side effects. Eighteen per cent did not respond to maximum medication. Thirty-two per cent discontinued treatment because of side effects. The side effects are reviewed and a death presumably due to prolonged hypotension is described.
ACCESSION #
16350111

 

Related Articles

  • THE USE OF ORAL HEXAMETHONIUM CHLORIDE (METHIUM�) IN THE TREATMENT OF HYPERTENSION. Kuhn, Paul H. // Angiology;Jun1953, Vol. 4 Issue 3, p195 

    A resume is given of our experience with the oral administration of a ganglionic blocking agent (Methium) in twenty-two selected cases of essential hypertension. Satisfactory reduction of blood pressure in the standing position and or relief of subjective symptoms were obtained in twenty cases....

  • TREATMENT OF HYPERTENSION WITH HYDERGINE: A REVIEW OF 200 CASES. Wilbrandt, R. // Angiology;Jun1953, Vol. 4 Issue 3, p183 

    1. 200 ambulant hypertensives were divided into two groups according to their funduscopic picture: 100 �mild� cases with fundi I and II and 100 �severe� cases with fundi III and IV. 2. Initial treatment was started with from 10 to 20 Hydergine injections of 1 cc daily or...

  • Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension. Feldman, Ross D.; Campell, Norman R.C.; Larochelle, Pierre // CMAJ: Canadian Medical Association Journal Supplement;12/14/1999 Hypertension, Vol. 161 Issue 12, pS18 

    Presents case studies and clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension. Differences in the treatment of specific cases of hypertension; Use of drugs to lower blood pressure.

  • Compliance in hypertension: Why don't patients take their pills? Myers, Martin G. // CMAJ: Canadian Medical Association Journal;1/12/99, Vol. 160 Issue 1, p64 

    Discusses a Canadian Heart Health Survey on Canadians with hypertension and findings of poor compliance with long-term antihypertensive therapy. Factors that contribute to poor compliance; Results of another study on the behavior of patients taking medication for unstable angina; Factors...

  • Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Caro, J. Jaime; Speckman, Jeanne L.; Salas, Maribel; Raggio, Gabriel; Jackson, Joseph D. // CMAJ: Canadian Medical Association Journal;1/12/99, Vol. 160 Issue 1, p41 

    Presents a medical study that examines the relation of persistence with treatment to the class of antihypertensive drug initially chosen. Methods; Results; Conclusions.

  • Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. Nuesch, Reto; Schroeder, Kerstin; Dieterle, Thomas; Martina, Benedict; Battegay, Edouard // BMJ: British Medical Journal (International Edition);7/21/2001, Vol. 323 Issue 7305, p142 

    Conclusion: Non-compliance with treatment was not more prevalent in patients with treatment resistant hypertension than in treatment responsive patients.

  • Turn to 796.2 for White Coat Hypertension.  // Neurosurgery Coding Alert;Feb2015, Vol. 16 Issue 2, p15 

    The article presents questions and answers related to hypertension including what is white coat hypertension, report ambulatory monitoring, and treatment for hypertension.

  • Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure. O'Dell, Kate M.; Kalus, James S.; Kucukarslan, Suzan; Czerska, Barbara // American Journal of Health-System Pharmacy;3/15/2005, Vol. 62 Issue 6, p606 

    Purpose. The impact of adding nesiritide to standard therapy and positive inotropic agents in patients with end-stage heart failure and secondary pulmonary hypertension (PH) was studied. Methods. Patients included in this retrospective study were 18 years of age or older, admitted to the...

  • Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors. Bourgault, Chantal; Elstein, Eleanor; Le Lorier, Jacques; Suissa, Samy // CMAJ: Canadian Medical Association Journal;8/10/99, Vol. 161 Issue 3, p255 

    Assesses whether patients treated for hypertension with various angiotensin-converting enzyme (ACE) inhibitors differed in their utilization of health care services and whether various ACE inhibitors should be considered therepeutically equivalent. Background; Methods; Results; Interpretation.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics